{"id":"biphasic-remogliflozin-etabonate","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Increased risk of hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SGLT2 inhibitors work by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine. This results in decreased glucose levels in the blood, which can help lower blood sugar levels in people with diabetes. By inhibiting SGLT2, Biphasic Remogliflozin Etabonate helps to reduce glucose reabsorption and increase glucose excretion.","oneSentence":"Biphasic Remogliflozin Etabonate is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:24:29.599Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02537470","phase":"PHASE2","title":"Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"BHV Pharma","startDate":"2015-07","conditions":"Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2","enrollment":191}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Biphasic Remogliflozin Etabonate","genericName":"Biphasic Remogliflozin Etabonate","companyName":"BHV Pharma","companyId":"bhv-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Biphasic Remogliflozin Etabonate is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}